- Home
- HRL vs BMRN Comparison
HRL vs BMRN Comparison
Compare HRL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRL
- BMRN
- Stock Information
- Founded
- HRL 1891
- BMRN 1996
- Country
- HRL United States
- BMRN United States
- Employees
- HRL N/A
- BMRN N/A
- Industry
- HRL Meat/Poultry/Fish
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- HRL Consumer Staples
- BMRN Health Care
- Exchange
- HRL Nasdaq
- BMRN Nasdaq
- Market Cap
- HRL 11.9B
- BMRN 9.9B
- IPO Year
- HRL N/A
- BMRN 1999
- Fundamental
- Price
- HRL $22.40
- BMRN $55.02
- Analyst Decision
- HRL Buy
- BMRN Buy
- Analyst Count
- HRL 6
- BMRN 19
- Target Price
- HRL $29.17
- BMRN $90.26
- AVG Volume (30 Days)
- HRL 5.0M
- BMRN 2.8M
- Earning Date
- HRL 12-04-2025
- BMRN 10-27-2025
- Dividend Yield
- HRL 5.12%
- BMRN N/A
- EPS Growth
- HRL N/A
- BMRN 59.53
- EPS
- HRL 1.37
- BMRN 2.68
- Revenue
- HRL $12,058,590,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- HRL $3.00
- BMRN $13.32
- Revenue Next Year
- HRL $2.28
- BMRN $7.51
- P/E Ratio
- HRL $16.54
- BMRN $20.23
- Revenue Growth
- HRL 0.65
- BMRN 12.39
- 52 Week Low
- HRL $21.03
- BMRN $50.76
- 52 Week High
- HRL $33.80
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- HRL 43.53
- BMRN 55.79
- Support Level
- HRL $22.21
- BMRN $50.76
- Resistance Level
- HRL $21.64
- BMRN $55.34
- Average True Range (ATR)
- HRL 0.53
- BMRN 1.76
- MACD
- HRL 0.15
- BMRN 0.34
- Stochastic Oscillator
- HRL 49.56
- BMRN 68.21
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (62% of fiscal 2024 sales), US foodservice (32%), and international (6%). By product, 72% of fiscal 2024 sales were from perishable food and 28% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.